This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Hisamitsu Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Der Gewinn von Hisamitsu Pharmaceutical wird voraussichtlich um 1.7% pro Jahr zurückgehen, während der Jahresumsatz um 4% pro Jahr wachsen soll. Der Gewinn je Aktie wird voraussichtlich um 0.2% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 4.9% betragen.

Wichtige Informationen

-1.7%

Wachstumsrate der Gewinne

0.21%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	12.6%
Wachstumsrate der Einnahmen	4.0%
Zukünftige Eigenkapitalrendite	4.90%
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Apr 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Analyseartikel • Jan 06

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) shareholders have had their patience rewarded with a 25% share price...

Analyseartikel • Jan 05

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Analyseartikel • Dec 18

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its periodic dividend on the...

Analyseartikel • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) periodic dividend will be increasing on the 7th of November to...

Analyseartikel • Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will increase its dividend on the 7th of November to ¥60.00, which is...

Analyseartikel • Apr 18

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Unsurprisingly, Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) stock price was strong on the back of its healthy...

Analyseartikel • Mar 07

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Analyseartikel • Feb 17

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analyseartikel • Jan 13

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analyseartikel • Dec 30

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analyseartikel • Nov 27

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will pay a dividend of ¥45.00 on the 26th of May. Based on this...

Analyseartikel • Nov 08

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Analyseartikel • Nov 04

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Analyseartikel • Oct 17

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) healthy profit numbers didn't contain any surprises for investors. We...

Analyseartikel • Sep 16

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...

Analyseartikel • Aug 20

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) dividend will be increasing from last year's payment of the same...

Analyseartikel • Jul 26

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be paying its dividend of...

Analyseartikel • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analyseartikel • Jun 27

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analyseartikel • Jun 13

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Analyseartikel • Apr 09

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

With a price-to-earnings (or "P/E") ratio of 20.9x Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) may be sending...

Analyseartikel • Mar 18

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Gewinn- und Umsatzwachstumsprognosen

TSE:4530 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
2/28/2029	176,797	13,067	N/A	16,324	1
2/29/2028	167,285	12,014	4,281	14,904	1
2/28/2027	159,685	11,973	5,665	16,289	1
2/28/2026	163,024	19,160	9,428	17,478	N/A
11/30/2025	159,267	19,988	N/A	N/A	N/A
8/31/2025	155,493	19,682	8,355	16,556	N/A
5/31/2025	154,861	19,534	N/A	N/A	N/A
2/28/2025	156,006	21,758	4,991	18,765	N/A
11/30/2024	150,132	15,537	N/A	N/A	N/A
8/31/2024	150,185	14,650	176	18,593	N/A
5/31/2024	145,420	14,708	N/A	N/A	N/A
2/29/2024	141,706	13,969	5,152	18,188	N/A
11/30/2023	139,276	14,330	N/A	N/A	N/A
8/31/2023	135,688	13,655	2,186	12,416	N/A
5/31/2023	134,033	14,160	N/A	N/A	N/A
2/28/2023	128,330	11,742	4,819	12,727	N/A
11/30/2022	125,411	12,962	N/A	N/A	N/A
8/31/2022	121,261	11,160	8,832	12,698	N/A
5/31/2022	118,825	8,927	N/A	N/A	N/A
2/28/2022	120,193	9,658	15,006	19,199	N/A
11/30/2021	120,351	9,746	N/A	N/A	N/A
8/31/2021	120,135	10,559	12,153	15,796	N/A
5/31/2021	117,389	11,499	N/A	N/A	N/A
2/28/2021	114,510	9,250	1,901	5,289	N/A
11/30/2020	122,736	8,996	N/A	N/A	N/A
8/31/2020	130,517	14,839	19,468	23,638	N/A
5/31/2020	136,641	16,894	N/A	N/A	N/A
2/29/2020	140,992	18,694	23,669	27,395	N/A
11/30/2019	139,912	21,295	N/A	N/A	N/A
8/31/2019	137,425	17,594	N/A	16,497	N/A
5/31/2019	139,142	17,665	N/A	N/A	N/A
2/28/2019	143,408	19,204	N/A	15,772	N/A
11/30/2018	140,891	16,608	N/A	N/A	N/A
8/31/2018	143,791	18,891	N/A	21,587	N/A
5/31/2018	145,288	18,897	N/A	N/A	N/A
2/28/2018	147,870	19,119	N/A	30,453	N/A
11/30/2017	145,749	17,895	N/A	N/A	N/A
8/31/2017	144,941	20,495	N/A	25,077	N/A
5/31/2017	143,853	19,540	N/A	N/A	N/A
2/28/2017	145,925	20,395	N/A	19,910	N/A
11/30/2016	149,298	20,806	N/A	N/A	N/A
8/31/2016	153,871	17,694	N/A	27,819	N/A
5/31/2016	160,325	18,778	N/A	N/A	N/A
2/29/2016	161,852	17,784	N/A	30,923	N/A
11/30/2015	164,086	19,626	N/A	N/A	N/A
8/31/2015	162,119	18,586	N/A	25,757	N/A
5/31/2015	158,667	18,321	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4530Für die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1.7% pro Jahr).

Ertrag vs. Markt: 4530Für die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1.7% pro Jahr).

Hohe Wachstumserträge: 4530Für die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: 4530Die Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt JP (6.5% pro Jahr).

Hohe Wachstumseinnahmen: 4530Die Einnahmen des Unternehmens (4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4530Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (4.9%).

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/14 07:58
Aktienkurs zum Tagesende	2026/05/08 00:00
Gewinne	2026/02/28
Jährliche Einnahmen	2026/02/28

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Hisamitsu Pharmaceutical Co., Inc. wird von 10 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Ritsuo Watanabe	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc
Akitada Iwasa	Daiwa Securities Co. Ltd.

This company listing is no longer active

Hisamitsu Pharmaceutical Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 10% to JP¥4,350

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Price target decreased by 15% to JP¥4,250

Recent updates

Hisamitsu Pharmaceutical Co., Inc.(TSE:4530) dropped from FTSE All-World Index (USD)

Full year 2026 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 28, 2026

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2026 Results on Apr 13, 2026

New major risk - Revenue and earnings growth

Taiyo Kosan Co., Ltd. completed the acquisition of additional 59.38% stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) from Takasago International Corporation (TSE:4914), Yomeishu Seizo Co.,Ltd. (TSE:2540), The Bank of Saga Ltd. (TSE:8395) and others for approximately ¥250 billion.

Third quarter 2026 earnings released: EPS: JP¥69.15 (vs JP¥62.32 in 3Q 2025)

Hisamitsu Pharmaceutical Co., Inc. Revises Dividend Guidance for the Fiscal Year Ending February 28, 2026

New minor risk - Share price stability

Taiyo Kosan Co., Ltd. agreed to acquire a %97.49 stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) in a management buyout transaction for approximately ¥380.6 billion.

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 18%

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

Does Hisamitsu Pharmaceutical (TSE:4530) Deserve A Spot On Your Watchlist?

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥60.00

First half dividend of JP¥60.00 announced

Hisamitsu Pharmaceutical's (TSE:4530) Earnings Are Of Questionable Quality

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of JP¥60.00 per share

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Price target decreased by 10% to JP¥4,350

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 3,000,000 shares, representing 4.09% for ¥15,000 million.

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Final dividend increased to JP¥60.00

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Hisamitsu Pharmaceutical Co., Inc. Announces Exiting of Sugiyama, Kosuke as Director

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 22, 2025

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2026 Results on Oct 09, 2025

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2025 Results on Apr 10, 2025

Upcoming dividend of JP¥45.00 per share

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

Third quarter 2025 earnings released: EPS: JP¥62.32 (vs JP¥48.25 in 3Q 2024)

Hisamitsu Pharmaceutical Co., Inc. Announces Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2025 Results on Jan 09, 2025

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

First half dividend of JP¥45.00 announced

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Upcoming dividend of JP¥45.00 per share

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024